Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia

NCT00002925 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

410

Enrollment

NIH

Sponsor class

Conditions

Leukemia

Interventions

DRUG: ara-C
DRUG: Daunorubicin
DRUG: Etoposide
DRUG: PSC-833
BIOLOGICAL: Aldesleukin

Sponsor

National Cancer Institute (NCI)